Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Approved by the FDA in May 2024, Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward outlook. Now, management expects 2025 revenue to fall into a range between ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 revenue guidance, based on relatively weak demand for its Covid and RSV shots. The latest guidance reduction was the ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...